Cellectis (FRA:ZVAA) E10: €-1.78 (As of Mar. 2026)


FRA:ZVAA Cellectis SA FRA:ZVAA
63 GF Score
Price €2.82
GF Value €2.63
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cellectis E10?

Cellectis FRA:ZVAA +14.63% 63 E10 is €-1.78 as of Mar. 2026. GuruFocus rates FRA:ZVAA with a GF Score™ of 63/100 and a GF Value™ of €2.63 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cellectis's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.156. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.78 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cellectis was 1.70% per year. The lowest was -0.70% per year. And the median was 0.50% per year.

As of today (2026-07-04), Cellectis's current stock price is €2.82. Cellectis's E10 for the quarter that ended in Mar. 2026 was €-1.78. Cellectis's Shiller PE Ratio of today is .


Cellectis  (FRA:ZVAA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cellectis E10 Related Terms


Cellectis E10 Historical Data

* Premium members only.

The historical data trend for Cellectis's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis E10 Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.73 -2.17 -2.18 -1.57 -1.90

Cellectis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.85 -1.77 -1.84 -1.90 -1.78

FRA:ZVAA vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Cellectis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Shiller PE Ratio falls into.


FRA:ZVAA
63GF Score
Cellectis SA FRA:ZVAA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cellectis's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.156/122.4300*122.4300
=-0.156

Current CPI (Mar. 2026) = 122.4300.

Cellectis Quarterly Data

per share eps CPI Adj_EPS
201606 -0.178 100.630 -0.217
201609 -0.356 100.340 -0.434
201612 -0.349 100.650 -0.425
201703 -0.524 101.170 -0.634
201706 -0.668 101.320 -0.807
201709 -0.612 101.330 -0.739
201712 -0.642 101.850 -0.772
201803 -0.576 102.750 -0.686
201806 -0.146 103.370 -0.173
201809 -0.463 103.560 -0.547
201812 -0.466 103.470 -0.551
201903 -0.319 103.890 -0.376
201906 -0.699 104.580 -0.818
201909 -0.345 104.500 -0.404
201912 -0.792 104.980 -0.924
202003 0.425 104.590 0.497
202006 -0.675 104.790 -0.789
202009 -0.603 104.550 -0.706
202012 -0.781 104.960 -0.911
202103 -0.235 105.750 -0.272
202106 -0.730 106.340 -0.840
202109 -0.697 106.810 -0.799
202112 -0.841 107.850 -0.955
202203 -0.636 110.490 -0.705
202206 -0.397 112.550 -0.432
202209 -0.636 112.740 -0.691
202212 -0.557 114.160 -0.597
202303 -0.542 116.790 -0.568
202306 -0.185 117.650 -0.193
202309 -0.290 118.260 -0.300
202312 -0.624 118.390 -0.645
202403 -0.138 119.470 -0.141
202406 -0.260 120.200 -0.265
202409 -0.207 119.560 -0.212
202412 0.076 119.950 0.078
202503 -0.166 120.380 -0.169
202506 -0.208 121.360 -0.210
202509 0.009 120.950 0.009
202512 -0.222 120.900 -0.225
202603 -0.156 122.430 -0.156

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.78 mean?
Cellectis (FRA:ZVAA) has a E10 of €-1.78 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cellectis and its competitors.
Is Cellectis' E10 too high?
Cellectis' current E10 is €-1.78. Overall, Cellectis has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' E10 compare to VRTX and REGN?
Cellectis' E10 of €-1.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cellectis and its competitors. Cellectis's current E10 is €-1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (FRA:ZVAA) is currently considered Fairly Valued. The stock's GF Value™ is €2.63, compared to a current price of €2.82 — trading 7.2% above its estimated fair value. The current E10 is €-1.78. Cellectis' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cellectis (FRA:ZVAA), the current E10 is €-1.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cellectis (FRA:ZVAA) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of €2.82 is trading 7.2% above its estimated GF Value™ of €2.63. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for FRA:ZVAA:

  • E10: €-1.78
  • GF Value™: €2.63 vs. price of €2.82 (7.2% above fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:ZVAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
63GF Score

Get the complete analysis for FRA:ZVAA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.82
Price
€2.63
GF Value